Sign Out
The following adverse reactions have been reported with estrogen/progestogen therapy:
Genitourinary System: Breakthrough bleeding, spotting, dysmenorrhea, premenstrual-like syndrome, increase in size of uterine fibroids, vaginal candidiasis, change in cervical erosion and in degree of cervical secretion, cystitis-like syndrome.
Breast: Tenderness, enlargement.
Gastrointestinal: Nausea, vomiting, abdominal cramps, bloating, cholestatic jaundice.
Skin: Chloasma or melasma which may persist when Femoston Conti is discontinued, erythema multiforme, erythema nodosum, hemorrhagic eruption, itching, allergic skin reactions.
Eyes: Steepening of corneal curvature, intolerance to contact lenses.
Central Nervous System: Headaches, migraine, dizziness, mental depression, chorea.
Miscellaneous: Increase or decrease in weight, changes in carbohydrate metabolism, aggravation of porphyria, edema, changes in libido, leg cramps.
View ADR Reporting Link
Continue with Google